Rainbow BioSciences, LLC: Could Stem Cells be Key to Promising Autism Therapy?
Published: Oct 16, 2012
NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB: RBCC) subsidiary Rainbow BioSciences will keep a close eye on a new study that could potentially lead to stem cell therapies for children with autism. Researchers have been given the go-ahead by the FDA to launch a small study evaluating the effectiveness of autism treatments using patients’ own umbilical cord blood. Thirty children, aged two to seven, will receive injections of their own stem cells from the cord blood banked by their parents at birth.